These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 30964361)

  • 1. Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia.
    Cortes JE; Muresan B; Mamolo C; Cappelleri JC; Crescenzo RJ; Su Y; Gambacorti-Passerini C; Heeg B; Douglas Smith B
    Curr Med Res Opin; 2019 Sep; 35(9):1615-1622. PubMed ID: 30964361
    [No Abstract]   [Full Text] [Related]  

  • 2. An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia.
    Muresan B; Mamolo C; Cappelleri JC; Leip E; Viqueira A; Heeg B
    Curr Med Res Opin; 2021 May; 37(5):801-809. PubMed ID: 33733983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.
    Cortes JE; Khoury HJ; Kantarjian HM; Lipton JH; Kim DW; Schafhausen P; Matczak E; Leip E; Noonan K; Brümmendorf TH; Gambacorti-Passerini C
    Am J Hematol; 2016 Dec; 91(12):1206-1214. PubMed ID: 27531525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.
    Khoury HJ; Cortes JE; Kantarjian HM; Gambacorti-Passerini C; Baccarani M; Kim DW; Zaritskey A; Countouriotis A; Besson N; Leip E; Kelly V; Brümmendorf TH
    Blood; 2012 Apr; 119(15):3403-12. PubMed ID: 22371878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefits and risks of ponatinib versus bosutinib following treatment failure of two prior tyrosine kinase inhibitors in patients with chronic phase chronic myeloid leukemia: a matching-adjusted indirect comparison.
    Levy MY; McGarry LJ; Huang H; Lustgarten S; Chiroli S; Iannazzo S
    Curr Med Res Opin; 2019 Mar; 35(3):479-487. PubMed ID: 30086654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study.
    Smith BD; Brümmendorf TH; Roboz GJ; Gambacorti-Passerini C; Charbonnier A; Viqueira A; Leip E; Purcell S; Goldman EH; Giles F; Ernst T; Hochhaus A; Rosti G
    Leuk Res; 2024 Apr; 139():107481. PubMed ID: 38484432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib.
    Brümmendorf TH; Cortes JE; Khoury HJ; Kantarjian HM; Kim DW; Schafhausen P; Conlan MG; Shapiro M; Turnbull K; Leip E; Gambacorti-Passerini C; Lipton JH
    Br J Haematol; 2016 Jan; 172(1):97-110. PubMed ID: 26537529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting.
    Muresan B; Mamolo C; Cappelleri JC; Postma MJ; Heeg B
    Appl Health Econ Health Policy; 2021 Nov; 19(6):929-940. PubMed ID: 34250585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study.
    Hochhaus A; Gambacorti-Passerini C; Abboud C; Gjertsen BT; Brümmendorf TH; Smith BD; Ernst T; Giraldo-Castellano P; Olsson-Strömberg U; Saussele S; Bardy-Bouxin N; Viqueira A; Leip E; Russell-Smith TA; Leone J; Rosti G; Watts J; Giles FJ;
    Leukemia; 2020 Aug; 34(8):2125-2137. PubMed ID: 32572189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML.
    Jain AG; Gesiotto Q; Ball S; Nodzon L; Rodriguez A; Chan O; Padron E; Kuykendall A; Komrokji R; Sallman DA; Lancet JE; Pinilla-Ibarz J; Sweet K
    Ann Hematol; 2024 Jun; 103(6):1941-1945. PubMed ID: 38634915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.
    Giles FJ; Abruzzese E; Rosti G; Kim DW; Bhatia R; Bosly A; Goldberg S; Kam GL; Jagasia M; Mendrek W; Fischer T; Facon T; Dünzinger U; Marin D; Mueller MC; Shou Y; Gallagher NJ; Larson RA; Mahon FX; Baccarani M; Cortes J; Kantarjian HM
    Leukemia; 2010 Jul; 24(7):1299-301. PubMed ID: 20520639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program.
    García-Gutiérrez V; Martinez-Trillos A; Lopez Lorenzo JL; Bautista G; Martin Mateos ML; Alvarez-Larrán A; Iglesias Pérez A; Romo Collado A; Fernandez A; Portero A; Cuevas B; Ruiz C; Romero E; Ortega F; Mata I; Tallón J; García Garay Mdel C; Ramirez Sánchez MJ; de Las Heras N; Giraldo P; Bobillo S; Guinea JM; Deben G; Valencia S; Sebrango A; Boqué C; Maestro B; Steegmann JL
    Am J Hematol; 2015 May; 90(5):429-33. PubMed ID: 25683327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Syed YY; McCormack PL; Plosker GL
    BioDrugs; 2014 Feb; 28(1):107-20. PubMed ID: 24420842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study.
    Zhang X; Xu N; Yang Y; Lin H; Liu B; Du X; Liu X; Liang R; Chen C; Huang J; Zhu H; Pan L; Wang X; Li G; Liu Z; Zhang Y; Liu Z; Hu J; Liu C; Li F; Yang W; Meng L; Han Y; Lin L; Zhao Z; Tu C; Zheng C; Bai Y; Zhou Z; Chen S; Qiu H; Yang L; Sun X; Sun H; Zhou L; Liu Z; Wang D; Guo J; Pang L; Zeng Q; Suo X; Zhang W; Zheng Y; Zhang Y; Li W; Jiang Q
    Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):e257-e266. PubMed ID: 38461040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
    Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
    Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 1/2 study of bosutinib in Japanese adults with Philadelphia chromosome-positive chronic myeloid leukemia.
    Nakaseko C; Takahashi N; Ishizawa K; Kobayashi Y; Ohashi K; Nakagawa Y; Yamamoto K; Miyamura K; Taniwaki M; Okada M; Kawaguchi T; Shibata A; Fujii Y; Ono C; Ohnishi K
    Int J Hematol; 2015 Feb; 101(2):154-64. PubMed ID: 25540064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bosutinib for the treatment of chronic myeloid leukemia in chronic phase.
    Quintás-Cardama A; Kantarjian H; Cortes J
    Drugs Today (Barc); 2012 Mar; 48(3):177-88. PubMed ID: 22462037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.
    Stansfield L; Hughes TE; Walsh-Chocolaad TL
    Ann Pharmacother; 2013 Dec; 47(12):1703-11. PubMed ID: 24396109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients.
    Scalzulli E; Caocci G; Efficace F; Rizzo L; Colafigli G; Di Prima A; Pepe S; Fegatelli DA; Carmosino I; Diverio D; Latagliata R; La Nasa G; Martelli M; Foà R; Breccia M
    Ann Hematol; 2021 May; 100(5):1213-1219. PubMed ID: 33677654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
    Pavey T; Hoyle M; Ciani O; Crathorne L; Jones-Hughes T; Cooper C; Osipenko L; Venkatachalam M; Rudin C; Ukoumunne O; Garside R; Anderson R
    Health Technol Assess; 2012; 16(42):iii-iv, 1-277. PubMed ID: 23134589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.